Wells Fargo Maintains Overweight on Health Catalyst, Lowers Price Target to $5
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Stan Berenshteyn maintains Health Catalyst (NASDAQ:HCAT) with a Overweight and lowers the price target from $6 to $5.
Wells Fargo analyst Stan Berenshteyn maintains Health Catalyst (NASDAQ:HCAT) with a Overweight and lowers the price target from $6 to $5.